Sweden's SenzaGen Q2 revenue rises 13% on VitroScreen turnaround
Sweden's SenzaGen Q2 revenue rises 13% on VitroScreen turnaround
Overview
Sweden non-animal testing firm's Q2 revenue rose 13% yr/yr to SEK 15.3 mln
Company's EBIT loss narrowed and EPS improved compared to prior year
Gross margin remained in line with historical levels, positive operating cash flow reported
Outlook
Company expects EU animal testing phase-out to strengthen long-term market prospects
Turnaround at VitroScreen progressing, with order intake increasing year-on-year and sequentially
SenzaGen says strategic initiatives and regulatory trends support long-term profitable growth
Result Drivers
VITROSCREEN TURNAROUND - Co said subsidiary VitroScreen saw increased order intake and received two major orders, supporting revenue growth
REGULATORY DEVELOPMENTS - EU roadmap to phase out animal testing expected to strengthen long-term market prospects for co's non-animal testing solutions
COST CONTROL - Co said effective cost base helped maintain gross margin in line with historical levels
Company press release: ID:nMFN599Jl3
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Sales |
| SEK 30.20 mln |
|
H1 Loss Per Share |
| SEK 0.13 |
|
Reuters Recommended Reads
Aug 19 - Sweden's SciBase H1 revenue rises
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Aug 19 - Sweden's Peptonic Medical Q2 sales drop, gross margin narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)